The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...

Tenosynovial giant cell tumor represents two distinct clinical presentations: localized (or nodular) and diffuse. Diffuse disease in tenosynovial giant cell tumors is highly irregular tumor shape and ...

Tenosynovial giant cell tumor is a rare condition of the joint that can cause symptoms like pain, swelling, and limited movement. Exercise tips from a physical therapist may help you maintain ...

Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, safety, and impact on patient quality of life.

Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology ...

A new dosing regimen for Turalio ® (pexidartinib) is now available for the treatment of adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional ...

About TGCT (PVNS/GCT-TS) TGCT, also referred to as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is a rare, typically non-malignant tumor that can be ...

Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor originating in the synovial lining of the joint, bursa, and tendon sheath. Since TGCT typically impacts individuals ...

An investigational drug, PLX3397 (Plexxikon, Daiichi Sankyo), has shown prolonged tumor regression in patients with tenosynovial giant cell tumor (TGCT), a rare disorder of the joints that leaves ...

The presentation, titled “Phase 1 Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DCC-3014 in Advanced Solid Tumors and Tenosynovial Giant Cell Tumor ...

GetNews Press Release.The Tenosynovial Giant Cell Tumors market size was valued approximately USD 300 million in 2023 and is anticipated to grow with a significant CAGR during the study period ...